Literature DB >> 17851532

Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors.

César Cobaleda1, Wolfram Jochum, Meinrad Busslinger.   

Abstract

Lineage commitment and differentiation to a mature cell type are considered to be unidirectional and irreversible processes under physiological conditions. The commitment of haematopoietic progenitors to the B-cell lineage and their development to mature B lymphocytes critically depend on the transcription factor encoded by the paired box gene 5 (Pax5). Here we show that conditional Pax5 deletion in mice allowed mature B cells from peripheral lymphoid organs to dedifferentiate in vivo back to early uncommitted progenitors in the bone marrow, which rescued T lymphopoiesis in the thymus of T-cell-deficient mice. These B-cell-derived T lymphocytes carried not only immunoglobulin heavy- and light-chain gene rearrangements but also participated as functional T cells in immune reactions. Mice lacking Pax5 in mature B cells also developed aggressive lymphomas, which were identified by their gene expression profile as progenitor cell tumours. Hence, the complete loss of Pax5 in late B cells could initiate lymphoma development and uncovered an extraordinary plasticity of mature peripheral B cells despite their advanced differentiation stage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17851532     DOI: 10.1038/nature06159

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  196 in total

Review 1.  Nuclear reprogramming to a pluripotent state by three approaches.

Authors:  Shinya Yamanaka; Helen M Blau
Journal:  Nature       Date:  2010-06-10       Impact factor: 49.962

Review 2.  Factors and networks that underpin early hematopoiesis.

Authors:  Elinore M Mercer; Yin C Lin; Cornelis Murre
Journal:  Semin Immunol       Date:  2011-09-18       Impact factor: 11.130

3.  The B-cell identity factor Pax5 regulates distinct transcriptional programmes in early and late B lymphopoiesis.

Authors:  Roger Revilla-I-Domingo; Ivan Bilic; Bojan Vilagos; Hiromi Tagoh; Anja Ebert; Ido M Tamir; Leonie Smeenk; Johanna Trupke; Andreas Sommer; Markus Jaritz; Meinrad Busslinger
Journal:  EMBO J       Date:  2012-06-05       Impact factor: 11.598

4.  Common clonal origin of an acute B-lymphoblastic leukemia and a Langerhans' cell sarcoma: evidence for hematopoietic plasticity.

Authors:  Richard Ratei; Michael Hummel; Ioannis Anagnostopoulos; Doris Jähne; Renate Arnold; Bernd Dörken; Stephan Mathas; Thomas Benter; Oliver Dudeck; Wolf-Dieter Ludwig; Harald Stein
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

5.  MiDReG: a method of mining developmentally regulated genes using Boolean implications.

Authors:  Debashis Sahoo; Jun Seita; Deepta Bhattacharya; Matthew A Inlay; Irving L Weissman; Sylvia K Plevritis; David L Dill
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

6.  Grand challenge commentary: Synthetic immunology to engineer human immunity.

Authors:  David A Spiegel
Journal:  Nat Chem Biol       Date:  2010-12       Impact factor: 15.040

7.  In vitro assays misrepresent in vivo lineage potentials of murine lymphoid progenitors.

Authors:  Lauren I Richie Ehrlich; Thomas Serwold; Irving L Weissman
Journal:  Blood       Date:  2010-12-16       Impact factor: 22.113

Review 8.  Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues.

Authors:  Jacob H Hanna; Krishanu Saha; Rudolf Jaenisch
Journal:  Cell       Date:  2010-11-12       Impact factor: 41.582

9.  Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells.

Authors:  Ernesto Lujan; Soham Chanda; Henrik Ahlenius; Thomas C Südhof; Marius Wernig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

Review 10.  Ovarian cancer stem cells: are they real and why are they important?

Authors:  Monjri M Shah; Charles N Landen
Journal:  Gynecol Oncol       Date:  2013-12-07       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.